MET基因相关汇总帖
深入解析MET扩增NSCLChttps://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58517MET基因突变及扩增肺癌https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58512&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
MET抑制剂的序贯用药策略https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58518&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
MET抑制剂的选择和轮换https://mp.weixin.qq.com/s/8oqvnbBb7bVkJ1zzgjWn2g
命运大转盘:MET TKI的继发突变耐药机制https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58511&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
曲美替尼使用说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58871&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
抗血管生成药治疗NSCLC https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59099&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
EGFR突变NSCLC患者的MET扩增耐药机制https://mp.weixin.qq.com/s/tgXkB-vzsi0c_fLjV-4vtg
火凤凰的治疗史https://mp.weixin.qq.com/s/ZQsSNX7HplKzl5fHWmBOIw
MET 14外显子跳跃突变、MET原发扩增和EGFR TKI耐药后产生的MET扩增是三类NSCLC的驱动基因。MET TKI可分成二类:I型(克唑替尼、INC280、X-396、Tepotinib和沃利替尼)和II型(卡博替尼、XL880、Merestinib和MGCD265)。
I型(克唑替尼、INC280、X-396、Tepotinib和沃利替尼)
克唑替尼(塞可瑞)使用说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58895&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
克唑替尼的心脏不良反应https://mp.weixin.qq.com/s/wV6J9l0HSjkl96YggNuMgQ
诺华的cMET新药INC280https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=9887&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
Capmatinib(INC280)https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58510&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
INC280使用说明https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=79763&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
INC280治疗MET ex14跳跃突变晚期NSLCC https://mp.weixin.qq.com/s/CTsNlbsatpC6IhMg_uWsxw
【ASCO2020】Capmatinib(INC280)治疗高度MET扩增晚期NSLCC https://mp.weixin.qq.com/s/TvRizsFSFdNzcCdy_9qBOA
新药:c-Met抑制剂Tepotinib https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58508&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
奥希替尼联合沃利替尼方案https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58519&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
MET基因改变导致ALK二代药耐药后,克唑替尼有效!https://mp.weixin.qq.com/s/LLPmAW-A1FtmA_rKdKCs_w
II型(卡博替尼、XL880、Merestinib和MGCD265)
Cabozantinib(XL184,卡博替尼)的服药说明https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=29051&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
XL184(卡博替尼)用药说明【整理版】https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=29206&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
卡博替尼(Cabozantinib,XL184)https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58507&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
卡博替尼治疗NSCLC一期临床结果https://mp.weixin.qq.com/s/4drLComPZZfWMYdswAIW7A
小分子MET抑制剂Merestinib一期临床结果https://mp.weixin.qq.com/s/dkecyh8u2ikpSi2xGWBqbA 啥是1型,2型? 收藏,感谢分享! 非常感谢! 收藏,感谢 感谢分享! 感谢分享!!!!!!!
页:
[1]